ASH Stock Recent News

Investors looking for breakout stocks to buy that Wall Street already loves should find it easier now that the S&P 500 is near 52-week and all-time highs. The index is up nearly 12% year to date thanks to an almost 5% gain in the past month.

Ashland (ASH) is set to sell its nutraceuticals business to Turnspire Capital Partners, with the deal expected to close in third-quarter 2024.

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investing style. Here's why you should take advantage.

Here is how Ashland (ASH) and Buenaventura (BVN) have performed compared to their sector so far this year.

Softer pricing hurts Ashland (ASH) sales for the fiscal second quarter.

Ashland beat on earnings but forecasted continued revenue sluggishness. The company sees some key end markets recovering and is lessening its reliance on some more cyclical products.

The headline numbers for Ashland (ASH) give insight into how the company performed in the quarter ended March 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Ashland (ASH) came out with quarterly earnings of $1.27 per share, beating the Zacks Consensus Estimate of $1.19 per share. This compares to earnings of $1.43 per share a year ago.

Ashland (ASH) reported earnings 30 days ago. What's next for the stock?

Ashland (ASH) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.